BME

BlackRock Health Sciences Trust

Stock NYSE – Stock Market Prices, News & Analysis

Investment fund specializing in the healthcare sciences sector, investing in pharmaceutical and biotechnology companies.

$ 39.85
0.59 %

BlackRock Health Sciences Trust

$ 39.85
0.59 %
BME

Investment fund specializing in the healthcare sciences sector, investing in pharmaceutical and biotechnology companies.

Price history of BlackRock Health Sciences Trust
Price history of BlackRock Health Sciences Trust

Performance & Momentum

6 Months 7.95 %
1 Year 16.87 %
3 Years 13.92 %
5 Years 11.06 %

Strategic Analysis

BlackRock Health Sciences Trust • 2026

BlackRock Health Sciences Trust is an investment fund focused on health sciences, combining concentrated exposure to U.S. pharmaceutical and biotechnology companies. Its differentiation lies in specialized active management, providing access to growth opportunities in a sector characterized by strong innovation and economic resilience.

Strengths
  • Targeted exposure to innovative companies in the pharmaceutical and biotechnology sectors
  • Active management by a recognized expert, supporting the selection of high-potential stocks
  • Solid performance over the medium and long term in a defensive sector
Weaknesses
  • Sensitivity to regulations and clinical developments that can affect valuation
  • Inherent volatility in the biotechnology segment, which is more exposed to operational risks
Momentum

Current momentum reflects a positive trend combined with good resilience in an often volatile environment, highlighting the continued appeal of the healthcare sector for investors seeking innovation and sector diversification.

Similar stocks to BlackRock Health Sciences Trust

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone